Pramipexole Conversion to Ropinirole Controlled Release (CR)

• Status: Completed
• Trial end date: 2008-05-01
• Target enrollment: 0
• Participant gender: All

Summary

A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rajesh Pahwa, MD
• Collaborator: GlaxoSmithKline
• Treatments: Pramipexole; Ropinirole

Criteria

Inclusion Criteria:

• Diagnosis of Parkinson Disease

• Currently taking pramipexole

• Never have taken Requip CR

Exclusion Criteria:

• Can not have significant adverse effects to standard Requip

• Can not have atypical PD due to drugs, metabolic disorders, encephalitis or degenerative diseases

• Can not have unstable medical conditions

• Can not be taking concurrent monoamine oxidase inhibitors except for selegiline (10mg per day or less)

• Female patients of childbearing potential must be using an effective method of contraception.

• Can not be pregnant or lactating.

This may not be a complete list; there may be additional criteria which may apply.